Viatris Inc (NASDAQ: VTRS) is a pharmaceutical company that develops, manufactures, and commercializes prescription drugs, including generic, branded, and complex dosage form products. The company generates revenue through product sales across multiple therapeutic categories sold to wholesalers, pharmacies, hospitals, and government purchasers globally. The 10-K filed February 26, 2026 for fiscal year ended December 31, 2025 references a $3.5 billion revolving credit facility dated September 27, 2024, indicating a debt-heavy capital structure. Viatris was formed from the combination of Mylan N.V. and Upjohn, and retains incentive plan structures inherited from Mylan's 2003 Long-Term Incentive Plan alongside its own 2020 Stock Incentive Plan. The company operates across multiple geographies. Based on the available filing excerpts, specific segment revenue figures, market share data, and named competitor details are not disclosed in the provided text.

Revenue model

Product sales of generic, branded, and complex pharmaceutical formulations sold on a transactional basis to distributors, pharmacies, hospitals, and government buyers. The company also pursues streamlined regulatory pathways including 505(b)(2) NDAs and ANDAs to bring products to market.

Products and services

Generic pharmaceuticals, branded pharmaceutical products, and complex dosage form drugs across multiple therapeutic categories. The company utilizes ANDA (Abbreviated New Drug Application) and 505(b)(2) regulatory pathways for product approvals.

Customers and end markets

Wholesalers, retail pharmacies, hospitals, and government purchasers. End markets include outpatient prescription drug consumers and institutional healthcare settings across global markets.

Value-chain role

Pharmaceutical manufacturer and commercializer occupying the mid-to-downstream position: drug development, manufacturing, regulatory filing, and distribution to trade customers.

Geographic exposure

Global operations across multiple geographies. Specific country-level revenue breakdowns are not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Bristol-Myers Squibb Co Catalent, Inc. Elanco Animal Health Inc Intra-Cellular Therapies, Inc. Johnson & Johnson Merck & Co Inc Organon & Co Royalty Pharma PLC Zoetis Inc